In order to evaluate the contribution of genetic defects in the pathogenesis of thrombosis, the laboratory investigation should include a functional APC-R lest, determination of the factor V genotype and measurements of plasma concentrations of PC, PS (total and free PS) and antithrorabin. In addition, a thrombin time will ensure that rare cases of dysfibrinogenemia are not overlooked. At present, available results suggest fibrinolytic parameters not to be of value in the evaluation of individual patients (2).
Before selecting the analytical procedure in the laboratory a number of questions should be addressed such äs what are the sensitivity and specificity of the laboratory assay for the genetic defect to be detected? Moreover, the assay performance such äs inter-and intra-day Variation are important factors to take into account. Quality control should be of high priority. In the choice of assay it is cracial to consider possible influence by other defects, e.g. APC-R influence on coagulation-based functional assays for PC and PS (see below). An important parameter to be taken into consideration is the predictive value of a positive and a negative lest. This is determined not only by the specificity and sensitivity of the assay but also by the prevalence in the population to be studied for the particular defect. Thus, unless the specificity is close to 100%, the predictive value of a positive lest is usually quite low for defects which are rare in the population. Examples of this will be given below. 
Anticoagulant Protein Deficiencies
A detailed evaluation of the possible contribution of anticoagulant protein deficiencies in the pathogenesis of thrombosis should include analysis of both protein levels with immunological assays and of the functional activity of each of these proteins. However, this is not always possible and practical compromises have to be made. In general, deficiencies of type I (low protein concentration) of any of the anticoagulant proteins are much more common than type Π deficiencies (low functional activity but normal protein concentration). An optimal assay for each of these proteins is an easy and cheap functional assay which detects both type I and type II deficiencies. In the case of antithrombin, there are several commercially available functional assays (based on Inhibition of either thrombin or factor Xa) which fulfill these criteria. An International Standard for antithrombin is available.
The Situation for PC and PS is more complicated because the available coagulation based functional assays are complicated to perform and several of them have low sensitivity and specificity. Assays devised to measure the protein concentrations are often cheaper and easier to perform than several of the commercially available functional assays, and consequently such assays are used in most laboratories in the primary evaluation of the patients. Both sensitivity and specificity of immunological äs well äs of functional assays are lower when used to lest individuals on oral anticoagulation than when used to test patients without anticoagulant therapy.
In the case of PC, depending on the site of the mutation there are many different possible types of functional defects. The interaction with the thrombin-thrombomodulin complex may for instance be impaired with a resulting poor activation; mutations in the vitamin K-dependent region may lead to poor phospholipid binding ability; mutations in other parts of PC may lead to functional defects due to poor interactions with either Substrates or cofactors. There is at present no easily available functional assay which monitors all functional aspects of PC and consequently, the laboratory evaluation is a practical compromise. A functional, easy, assay is available for PC and it is used in many laboratories äs an alternative to immunological assays in the primary screening of the thrombosis patients. The assay includes activation of PC in plasma with a PC activator (Protac) isolated from a snake venom and measurement of the proteolytic activity of the activated PC against a synthetic Substrate. The assay, which is readily automated, is available from several commercial sources. It shouid be borne in mind that the assay does not detect several of the type II detects. As there is an overlap m the PC concentrations between normals and those with the genetic defects (3), sensitivity and specificity of all available functional or immunological assays for the genetic defects causmg PC deficiency are below 100% The Protac based assays perform quite well and have coefficients of Variation below 2% The sensitivity has been estimated to be 85%, whereas the specificity is estimated to be 95% (3) When this assay is used to study a population m which the prevalence is around 0 3%, the predictive value of a positive test is 5% whereas the predictive value of a negative test 99 9% Thus, m screenmg of the general population this assay is excellent to exclude PC deficiency, whereas a positive test is caused by a genetic defect m only 5% of the cases When the assay is used to test patients with thrombosis (prevalence of genetic defect approximately 3%), the predictive value of a negative test is 34% whereas the predictive value to a positive test is 99 6% The predictive value of a positive test is negatively related to the PC level, t e the lower the PC level the higher the predictive value There is an International Standard for PC available At present, there are no functional PS assays which fulfill the requirements that can be put on an assay which is to be used m the pnmary evaluation of thrombosis patients The low specificity of the available functional assays is a major problem äs it has recently been shown that functional assays for PS are mfluenced by the APC-R associated with the presence of the factor V 506Arg to Gin mutation (4) As PS circulates m plasma both äs free protem (approximately 30%) and in complex with the C4b-bmdmg protem (5), a relevant question is which fraction of PS should be measured with the immunological assays, the free form, the bound form or total PS The current provisional conclusion is that the free PS assays have higher sensitivity and specificity for the genetic defects causmg PS deficiencies than assays for total PS This is because there is a great overlap m the total PS levels between normals and those with the genetic defect (6) Although the prevalence of PS deficiency m the general population is not well estabhshed it is reasonable to suspect that it is sirmlar to that of PC and the discussion about the predictive value for a negative and positive test (see above) is therefore relevant also for PS There are several commercially available assays for both free and total PS and an International Standard will become available
The APC-R Test
So far, practical chmcal expenence has mamly been obtamed with the APTT-based test for APC-R (7) In an APTT reaction, the addition of APC results m degradation of both factor Villa and factor Va, which delays thrombin generation and hence the formation of the fibnn clot The factor V 506Arg to Gin mutation is associated with partial resistance to degradation of mutated factor Va by APC but the mutated factor Va expresses normal procoagulant properties (8-10) Consequently, thrombin generation is not properly impaired m the presence of APC, which results m less Prolongation of the clottmg time
As the APC-R test is based on a Standard APTT-reaction it is easy to perform The APTT-reaction is run m the presence and absence of a carefully standardised amount of APC, which is mcluded in the calcium chlonde solution used to mitiate the clottmg reaction (7) The clottmg time is measured m the presence (a) and absence (b) of APC and a ratio (the APC-raüo) between the two clottmg times (a/b) is calculated If the assay is always done on the same Instrument and also m other respects performed under stnctly standardised conditions, the resultmg APCratios can be used äs they are (l l, 12) However, it has been observed that different Instruments give different clottmg times and APC-ratios obtamed on one type of Instrument cannot be directly compared with those from another type (13) If results from different laboratones are to be compared, it is beneficial to normahse the APC-ratios agamst the APC-ratio of a normal plasma pool (14) There are some nnportant considerations to take mto account m relation to such a normalisation procedure Due to the high prevalence of APC-R m the general population a pool of normal plasmas is fairly hkely to contam plasma from mdividuals with APC-R and m accordance with this, it has mdeed been found that APC-ratios of normal plasma pools are always lower than the mean of the mdividual APC-ratios For laboratones not havmg the possibihty to perform factor V genotypmg, a practical solution to the problem may be to exclude plasmas with extreme APC-ratios from the pool. eg the 5 or 10% with the highest and the 5 or 10% with the lowest APC-ratios In this context, it is obvious that an International Standard plasma would be useful
The handlmg of the plasma samples is probably of importance and the quahty of the results depend on stnct standardisaüon The centnfugation of blood should ensure that the resultmg plasma is platelet poor (<1% of normal platelet count), because e\en a small contammation ot platelets affects the APC-ratio, m particular after freezmg and thawmg of the plasma, platelet contammation will lower the APC-ratio (15) For routme purposes it is recommended to centnfuge the plasma at 2000 g for 20 mm at room temperature When the plasma is pipetted off, only the middle portion should preferably be utilised to avoid platelet contammation by native or disrupted platelets
The APC-R test can be performed on both fresh and frozen plasma but "like should be compared with like", i e \vhen fresh plasma is analysed, the normal ränge should have been determmed with fresh plas ma, when samples are frozen at -70° C or at -20° C they should be compared with normal controls handled in the same way In suppoit foi this concept, it was recently reported that freezmg of plasma results m decreased APC-R (Coatest® APC™ Resistance from Chromogemx Molndal, Sweden, was used m the study) but of practical impoitance the authors found no differences between freezmg tempeiatures (-70° C and -30° C tested) (14) When all variables are stnctly controlled, the APC-R test is rehable and gi\es good discnmination between normal and APC-R mdividuals The reported sensitivity and specificity of the APC-R test for factor V 506Arg to Gin aie 85-95% or better Variation m endogenous levels of PC has of couise, no mfluence on the APC-R because a standardised amount of APC is added In addition, Variation of the endogenous free PS level withm the ränge expected for heterozygous PS deficiency and normals has no or only a very mmor mfluence on the APC response m the APTT-based assay (7,14)
The original APC-R test has a sensiti\ it\ of 94% tor detection of factor V 506 Gin allele, whereas the specificin is approximately 85% (sirmlar results have been found foi the commercial assay from Chi omogemx) If this test is used for scieenmg ot a population m which the prevalence is around 10%, the negative predictive value is 99 7% whereas the positive predictive value is onh 16% In screenmg a population with thrombosis the negative predicme \dlue is 97% whereas the positive predictive value is around 73% Thus a positive test should always be confirmed by factor V genonpmg The sensitivity and specificity of the APC-R test appears to be lelated to the quahty of the APTT reagent
The original APC-R test is not lehable tor analvsis ot plasmas hom mdividuals receivmg oral anticoagulants or hepann 01 it they are denved from mdividuals with other coagulation detects such äs lupus anticoagulants or coagulation factor dehcienues (11 14) In plasma from patients on oral vitamm K antagomsts the dottmg times m the presence of APC are usually quite long (clottmg mav not even occur m such plasmas), which results in high ratios In order to allow analysis of such plasmas, a modified APC-R test, m which sample plasma is prediluted with factor V deficient plasma before assay, was suggested (16-18) A predüution of l m 4 of sample plasma with factor V deficient plasma seems to provide sufficient amounts of Vitamin K-dependent coagulation factors in the assay to yield normal basal APTT This modification gives vahd results not only for patients on oral anticoagulation but has been found also to provide an improved discnmmation for the factor V 506 Arg to Gin mutation For some time this modification has been evaluated, usmg plasmas from mdividuals with or without oral anticoagulant therapy and a 100% sensitivity and speciftcity for the presence ot the factor V 506 Gin allele was obtamed, irrespective of the plasma origm Thus, the modified test is an excellent screenmg test for the presence of the factor V 506 Gin allele
Analysis for the Factor V 506Ar g to Gin Mutation
The codon for Arg506 is positioned close to the exon-mtron boundary in exon 10ofthefactorVgene(19) Determination ot the G to A mutation mvolves amphfication of this nucleotide region eithei from genomic DNA or from mRNA The detection of the point mutation can be made m many ways, e g by nucleotide sequencmg, by different hybndisation techniques, by restnction enzyme cleavage or by allele specific amplification (20-25) The methodology can be optirmsed to allow analysis of a large number of samples every day The rate limitmg step is usually the preparation of patient DNA, even though rather simple extraction procedures can be used It is important to recogmse the nsk of contammation of PCR-based assay s and hence it is of utmost importance to orgamse the work carefully and include both positive and negative controls
The APC-R Test vet ms the Factor V Gene Mutation Test
Optimal evaluation of a smgle patient requires both the functional APC-R test and the factor V gene mutation analysis to be used, because the two methods provide complementary Information However, for economical and practical reasons it will not always be possible to do both tests on all mdividuals Until more expenence is obtamed by mdividual mvestigators it seems that a rational approach would be to perform parallel APC-R tests m the absence and presence of factor V deficient plasma until confidence is obtamed with the latter Apart fiom allowmg analysis of plasma from mdividuals on oral anticoagulant therapy, this approach will also decrease the need foi confirmatory genetic testine the other genetic defects are less mteresting to evaluate for prophylactic screenmg are the relatively low levels of sensitivity and specificity which gives low predictive value of a positive test Cost-benefit analysis are required m the evaluation of prophylactic testmg
To date it has not been recommended to perform the laboratorv mvestigation m association with the acute thrombotic event mainly because most assays are difficult to Interpret and the therapeutic regimes may mfluence the results of the assays This recommendation may need to be re-evaluated with the availabihty of the modified highly specific and sensitive APC-R test (with factor V deticient plasma) and factor V genotypmg
Wheie Should the Laboiatoi~\ [nvestigatwn be Perfouned 7
The specialised assays for anticoagulant protem deficiencies are prefeiably performed m specialised coagulation umts whereas it is a matter of debate where the APC-R testmg should be done Time will give the APC-R testmg its nght role m practical medicme and it will at this stage become obvious whether the testmg should be periormed not only m specialised laboratories but also m major or smaller hospitals
Who Should be Tested?
This question is related to the questions what to test and why It is recommendable that testmg is performed on patients with thrombosis and possibly also on their first degree family members It is vahd to conclude that theie aie at piesent no data to support general screenmg of the population for APC-R Whether prophylactic APC-R testmg is beneficial m association with nsk situations is yet to be evaluated
Whv Should We Test for Genetic Defects Piedisposmg fot Thrombosis'
For each category of mdividuals it is impoitant to ask the question why the testmg is performed The most pertment question is whether the results of the assays will affect the handlmg of the patients This is true for both general screenmg and for mvestigation of thrombosis patients The lapid expansion of knowledge m this field will bring ne\v therapeutic lecommendations for mdividuals with genetic predisposition for thrombosis There are two major leasons for testmg of farmh members of patients with thrombosis the prophylactic and diagnostic purposes The prophylactic aspects lelate to the possibilities to give adequate advice to family members and the diagnostic purposes to make rehable diasnosis of mhented delects
When Is itAppropnate to Perfotm the Laboratorv Evaluation 7
At present most testmg is performed after a thrombotic episode and also after discontmuation ot the oral anticoagulation Most of the assays have their highest sensitivity and specificity for the genetic defects if this is stnctly followed Testmg for PC and PS is not rehable durmg oral anticoagulation and it is pieterable that the patient has been otf this kmd ot therapy for at least 10 days In raie cases it is possible to discontmue the therapy for 10 days dm mg which the patient receives heparm (Standard or low molecular weight hepann) A sample can be drawn on the mornmg ot the tenth day betöre the hepann admimstration It will be mteresting to evaluate whether piophylattic testmg ot APC-R betöre surgeiy oral contraception, hospitahsation will be beneticial Highly sensitive and specific assays for APC-R with high piedictive value aie available and mexpensive The mam leasons why
Clinical Manifestations of Inhented Thrombosis
The most common climcal problem is deep vein thrombosis of the lower hmbs, with 01 without pulmonarv embohsm, accountmg for approximately 90% of all the thrombotic episodes, Table l Unusual sites ot venous thrombosis, such äs those m the mesentenc or cerebral vems, account tor less than 5% of the total episodes in patients with antithiorabm PC 01 PS deficiencies m patients with APC-R thrombosis seems to occur less tiequently at these sites Supeihcial thiombophlebitis is moie trequent m patients with PC or PS dehciency and APC R than m antithiombm deficient patients Even though a t öle foi PS deliciency äs a nsk tactoi tor artenal thiombosis has been postulated, there is little current evidence that this or other heterozygous detects ot the antiooagulant Systems increase the nsk öl artenal thrombosis (28, 29) Frequent recurrences* Neonatal purpura fulmmans (homozygous protein C and protein S deficiency) -All these features are less evident m patients with APC-R, who appear to be less severely affected climcally There is history of thrombosis at diagnosis m 50-60% of mdividuals with antithrombm, PC and PS deficiencies, with a 50% recurrence rate, the first thrombotic episode occurs äs early äs before 40 years in approximately 80% of patients In antithrombm deficiency, the Overall nsk of venous thrombosis is considered greater than m PC or PS deficiency (30), but contradictory results have been obtamed (29) On the other hand, mdividuals with APC-R appear to have a lesser tendency to thrombosis than those with the defects of the naturally occumng anticoagulants There is history of thrombosis m only 23% to 31% of cases with APC-R (l l, 24) and only 30% of them develop thrombosis before age 45 (31) The presence of APC-R however magmfies the nsk of thrombosis m patients with antithrombm, PC and PS deficiencies (32-34), äs discussed earlier
In antithrombm, PC and PS deficiencies 32% to 50% of the venous thrombotic episodes occur when other nsk factors are concomitantly present (surgery, pregnancy, immobihzation) (26-29) In mdividuals with APC-R, the need of the existence of such nsk factors to tngger thrombotic episodes appears to be greater (62%) than for the other thrombophilic syndromes (24) The nsk factors that are more often associated with the occurrence of thrombosis are pregnancy, the puerpenum and surgery (24,26,27,29) In women with antithrombm deficiency, the frequency of thrombosis dunng pregnancy and the puerpenum is between 37% and 44%, m PC or PS deficiency, between 12% and 19% (35,36), m APC-R, 28% (37) Thrombotic episodes occur most frequently during the puerpenum, accounting for 60-75% of all the episodes comphcating pregnancy (35, 36) A retrospective analysis of a large number of antithrombm, PC or PS deficient mdividuals gave an overall frequency of venous thrombosis comphcating surgery of 22%, with no sigmficant differences due to the type of deficiency or surgical procedure (36) Intake of oral contraceptives is associated with an mcreased thrombotic nsk, parücularly m women with antithrombm deticiency and APC-R (38, 39) Patients with dysfunctional defects of antithrombm, PC and PS have thrombotic nsks similai to those of the correspondmg quantitative defects A notable exception is the antithrombm HBS type II subtype, with a prevalence ot thrombosis m these (heterozygous) cases of only 6%, contrasting with 52-68% m patients with other types of antithrombm deficiencies (40) Homozygous antithrombm deficiency is extremely rare and almost exclusively reported m patients with HBS defects These mdividuals have a severe thrombotic history of early onset, often affecting artenes (41) Homozygous type I antithrombin deficiency is, presumably, mcompaüble with hfe in one report, two brothers with this defect died withm three weeks of birth (42) Homozygous PC deficiency has pecuhar phenotypic and chnical expressions [reviewed m (43) ] In patients with unmeasurable PC, purpura fulmmans. due to thrombosis of small vessels with cutaneous and subcutaneous ischemic necrosis, may occur soon after birth or m the first year of hfe (44, 45) In patients with very low but measurable PC (5-20%), chnical mamfestations are milder and generally similar to those for heterozygous deficiency (46) Homozygous PS deficiency has been rarely reported, but is also associated with neonatal purpura fulmmans (47) Due to the high frequency of the mutant factor V m the general population, homozygous APC-R is relatively frequent, ~1 5000(48) Whether homozygotes have a nsk of artenal thrombosis greater than that of the general population remams to be elucidated (49, 50) 
Management of Inhented Thrombophilia

Acute Events
The management of acute venous thrombosis or pulmonary embolism m patients with inhented thrombophiha is generally not different from other patients Thrombolytic therapy can be used m patients with massive acute venous thrombosis or pulmonary embolism Hepann should be mitiated with an intravenous bolus of 5,000 umts followed by an mfusion of 1400 umts per hour (51), or if a weight adjusted regimen is used, a bolus of 80 umts per kg body weight followed by an mfusion of 18 umts per kg per hour (52) The APTT should be performed approximately 6 hours after therapy is mitiated and at least daily thereafter to mamtam the clotting time in the therapeutic ränge For many commercial APTT reagents, this conesponds to an APTT that is l 8 to 3 0 times the mean of the noimal ränge or an anti-factor Xa heparm level of 0 3 to 0 7 umts per ml (53) For less sensitive APTT reagents, the therapeutic APPT ratio is l 5 to 2 0 (54) Warfarm can be started withm the first 24 h Heparm is contmued for at least 5 days (55) or until the prothrombm time is m the therapeutic ränge, namely an International Normahzed Ratio (INR) of 2 0 to 3 0 Patients with antithrombm deficiency can usually be treated successfully with intravenous heparm (56) , though m some situations unusually high doses of the drug are required to achieve adequate anticoagulation In antithrombm deficient patients receiving heparm for the treatment of acute thrombosis, the adjunctue role of antithrombm concentrate punfied from human plasma is not clearly defmed, äs controlled tnals have not been performed (56) This product should probably be admimstered when difficulty is encountered m achievmg adequate heparmization, or recurrent thrombosis is observed despite adequate anticoagulation It is also reasonable to treat antithrombm deficient subjects with concentrate before major surgenes or m obstetncal situations where the nsks of bleedmg from anticoagulation are unacceptable The manufactunng processes used to prepare antithrombm concentrate result m a product that is greater than 95% pure, they also mactivate the hepatitis B and C viruses and human immunodehciency virus I (57 58) Hence, it is preterable to admimster antithrombin concentrate rather than tresh trozen plasma
The mfusion ot 50 umts of antithrombm concentrate per kilogram ot body weight (one umt is defmed äs the amount ot antithrombm m one ml of pooled noimal human plasma) \\ill usually raise the plasma antithrombm level to approximately 120 r r m α congemtally deficient mdividual with a baselme level ot 50% (58-62) Plasma levels should be momtored to ensuie that they remam above 80%, the admmistration of 60% of the initial dose at 24 h mtervals is recommended to mamtain mhibitor levels in the normal ränge (62) Due to the intrequent occurrence of coumann-mduced skin necrosis, it may be advisable to take special precautions when mitiating oral anticoagulant treatment m a patient who is previously known or likely to have PC deficiency Warfann should be started only when the patient is fully hepannized and the dose of the drug should be mcreased gradually, stanmg from a relatively low level (e g, 2 mg for the first 3 days and then m increasmg amounts of 2 to 3 mg until therapeutic anticoagulation is achieved) Patients with heterozygous PC deficiency and a history of wartann induced skin necrosis have been successfully retreated with oral anticoagulants Here PC admmistration either in the form of fresh frozen plasma or PC concentrate provides protection agamst the development of recurrent skin necrosis until a stable level of anticoagulation is achieved (63, 64) After an episode of venous thrombosis or pulmonary embohsm, patients are usually contmued on oral anticoagulants for 3 to 6 months Recent data indicates that the nsk of recurrence is greater m patients with permanent äs opposed to temporary nsk factors for thrombosis (65, 66) and it is therefore appropnate that warfarm should be contmued for at least 6 months at an INR of 2 0 to 3 0 in patients with inhented thrombophilia After 6 months of anticoagulant treatment for an acute thrombotic event, an assessment must be made äs to the relative benefit conferred by long-term anticoagulant therapy in preventmg future thromboembohc comphcations versus the potential side-effects, cost, and mconvemence for the patient Unfortunately there is a paucity of rehable data regardmg the magmtude of the thrombotic nsk or the benefit of anticoagulant treatment m patients with deficiencies of antithrombm. PC, or PS äs these are relatively uncommon disorders Due to the high frequency of APC-R m patients presentmg with a first episode of venous thrombosis, rehable data is just emergmg regardmg the nsk of recurrence (67) At this time however. only general guidehnes (rather than rigid lecommendations) for managmg patients with the vanous hereditary defects predisposmg to thrombosis will be proposed
Inhented Tlu ombotic Disoideis and Recommendatwns Pertaming to Duratwn of Anticoagulant Tieatment
When a heterozygous patient with one of the hereditary thrombotic disorders is identified. tamily studies should be conducted since approximatelv half of their first-degree relatives will be affected Affected asyrnptomaüc mdividuals should receive counselmg regardmg the imphcations of the diagnosis and advice regardmg Symptoms that require immediate medical attention In women of child-beanng age, oral contraceptives are generally contramdicated m view of the mcreased thrombotic nsk associated with the use of these medications, although individual circumstances need to be taken mto consideration The replacement dose of estrogens that is admmistered to postmenopausal women is much lower than the contraceptive dose and has not been shown to mcrease the nsk of venous thrombosis in the general population (68) As theie are not currently data mdicatmg that these medications mcrease the nsk ot thrombosis m patients with a hereditary thrombotic disoider, postmenopausal estrogen leplacement is not absolutely contramdicated m women who have a strong mdication for replacement therapy All biochemicallv atteited mdividuals should be carefully evaluated pnor to surgical, medical or obstetnc protedures that carry an mcreased thrombotic nsk These subjects should then receive appropnate prophylactic anticoagulation regimens 1t specitic concentrates are available tor the patient's deficiency state, under some restncted circumstances these might also be admmistered to raise the plasma levels of the protem to the normal ränge dunng the pen-operative penod
In patients with an inhented thrombotic disorder, the occurrence of two or more spontaneously occumng thromboembohc episodes often leads to the contmuation of oral anticoagulants for life. even though some feel that the nsks of bleedmg could exceed those of recurrence of thrombosis Given that future events in an asymptomatic patient or m an individual with only one pnor thrombotic episode cannot currently be accurately predicted and that there is a fimte nsk of bleedmg associated with warfann therapy, recommendations relatmg to long-term anticoagulation are best mdividuahzed at the current time (69, 70) The climcal features that should be considered in making this decision mclude 1 Whether the thrombotic episodes were spontaneous or whether precipitatmg factors were present, e g, if a precipitatmg event such äs a major abdominal Operation was present, it would be reasonable to manage the patient without long-term oral anticoagulation after the acute episode was adequately treated 2 The sex and hfestyle of the individual, e g, situations where these factors may influence the decision-making process mclude women of child-beanng age planmng to conceive, occupations that entail prolonged penods of immobihzation and thereby might be associated with an mcreased nsk of thromboembohsm, jobs with higher than average chance of trauma that might lead to thrombotic or bleedmg comphcations 3 A history of thromboembohsm m other biochemically affected members of the family, though marked mtra-and mter-familial heterogeneity has been observed m the phenotypic expression of the mhented thrombotic disorders 4 The number, Sites, and seventy of thrombosis, e g , a patient who pieviously sustamed a massive pulmonary embolus is more likely to receive long-term warfann than a subject who developed deep venous thrombosis m a calf vem
Management ofPtegnancM
The management of pregnancies in women with hereditary thrombotic disorders poses special problems (71) äs formal studies evaluatmg treatments and exammmg decision analyses are unavadable The incidence ot thrombotic comphcations dunng pregnancy and the postpartum penod appears to be greater in women with antithrombm deticiency than m those with deficiencies of PC or PS (35) Recent data also indicates that 60% of women who develop a first episode of venous thrombosis dunng pregnancy have a diagnosis of APC-R (10) Durmg pregnancy, adjusted-dose heparm admmistered by the subcutaneous route is the anticoagulant of choice m many Centres because its efficacy and safety for the fetus are estabhshed (72) (Centres with increasmg expenence of low MW hepanns, howe\ er, might prefer to use this class of agent, m view of potentially simpler laboratory momtonng) Patients with a history ot thrombotic episodes should receive treatment throughout pregnancy, while affected women with antithrombm deficiencv who have not yet expenenced such events should probably receive treatment Treatment of asymptomatic women with other hereditary thrombotic disorders should be considered on an individual basis
The dose and duration of heparm therapy m pregnancy (and mdeed even its overall benetit) is uncertam äs uppropnately designed climcal tnals have not been pertormed m these patient populations Patients considered to be at high nsk should lecene tull-dose heparm by subcutaneous mjection every 12 h tor the duration ot pregnancy The dose of hepann should be adjusted to mamtain the 6 h postinjection-APTT l 5 times the control value In woraen considered to be at intermediate nsk, lower doses of heparm can be used (5,000 to 10,000 units subcutaneously every 12 h) and therapy can be started dunng the second or third trimester and contmued for approximately 6 weeks mto the postpartum penod Low nsk patients can be observed closely throughout the pregnancy with duplex ultrasound imagmg of the leg vems at regulär mtervals
In women who are planning pregnancy while chronically taking oral anticoagulants, several approaches can be taken to mmimize the nsk of both thrombotic comphcations and warfann erabryopathy One is to stop warfann and commence subcutaneous hepann therapy this potentially exposes the patient to many months of hepann therapy and the nsk of osteoporosis while she is trymg to conceive An approach in women with antithrombm deficiency is to use antithrombm concentrates until conception This product, however, is costly and needs to be admimstered mtravenously at frequent mtervals Fmally, warfann ther apy could be contmued with the performance of pregnancy tests on a frequent basis As soon äs pregnancy is diagnosed, and pnor to the sixth week of gestation, oral anticoagulants must be discontmued and heparm therapy mitiated Though the nsk of warfann embryopathy appears to be quite small dunng the first six weeks of pregnancy (73), even the small nsk of this complication makes this the least preferable of the three approaches
Coumann-mduced Skm Necrosis and Neonatal Purpurn fulmmans
A clear association has been estabhshed between the rare complication of coumann-induced skm necrosis and hereditary PC deficiency (63,74) About a third of patients with coumann-mduced skm necrosis will prove to have hereditary PC deficiency (75) This complication has also been descnbed m a patient with heterozygous PS deficiency (76) As coumann-induced skm necrosis is a rare complication, therapy has been guided pnmanly by knowledge regardmg its pathogenesis The diagnosis should be suspected m patients with painful, red skm lesions developing withm a few days after the Initiation of the drug and immediate Intervention is required to prevent rapid progression and reduce comphcations Therapy should consist of immediate discontmuaüon of warfann, admmistration of Vitamin K, and mfusion of hepann at therapeuüc doses Lesions, however, have been reported to progress despite adequate anticoagulation with hepann In patients with hereditary PC deficiency, the admmistration of a source of PC should be senously considered, and it may also be appropnate m other patients with warfar in-mduced skm necrosis äs they mvanably have reduced plasma levels of functional PC when the skm lesions first appear Fresh frozen plasma has been used, but improved results can be expected with the admmistration of a highly punfied PC concentrate, which facilitates the rapid and complete normahzation of plasma PC levels (77) The management of neonatal purpura fulmmans m association with homozygous or doubly heterozygous PC deficiency is more complicated and hepann therapy äs well äs antiplatelet agents have not been shown to be effective (44, (78) (79) (80) The admmistration of a source of PC appears to be cntical m the initial treatment of these patients Fresh frozen plasma has been used with success to treat these mfants However, the half-life of PC m the circulation is only about 6 to 12 hours (81, 82) , and the admimstration of plasma on a frequent basis is limited by the development of hyperprotememia, hypertension loss of venous access, and the potential for exposure to mfectious viral agents A highly punfied concentrate of PC has been developed and is efficacious m treatmg neonatal purpura tulminans (83) Wartarm has been admimstered to these mfants without the redevelopment of skm necrosis dunng the phased withdrawal of fresh frozen plasma mfusions (44, 80, (84) (85) (86) , and this medication has been used chronically to control the thrombotic diathesis A 20 month old child with hver failure and homozygous PC deficiency has undergone successful hver transplantation which normalized his PC levels and resolved the thrombotic diathesis (87) Neonatal purpura fulmmans has been descnbed in association with homozygous PS deficiency (88, 89) 
Prenatal Diagnosis in Inhented Thrombophilia
Prenatal diagnosis can only be considered appropnate m possible cases of severe thrombophiha where the fetus is expected to be homozygous or compound heterozygous for mhibitor deficiency Only m a few mstances has prenatal diagnosis been performed, m attempts to avoid severe thrombophiha The initial procedure used was fetal blood samplmg by cordocentesis dunng the 19th week of gestation m a woman who had previously delivered two newborns who died of massive thrombosis and purpura fulmmans due to homozygous PC deficiency (90) At this stage of gestation the mean level of PC antigen is about 10 U/dl (90) (91) (92) , and thus, care should be taken m distmguishmg between results consistent with heterozygosity with a PC level of about 5 U/dl and homozygosity In two reports the mean level of fiee PS antigen at 15-23 weeks of normal gestation was 27 and 38 U/dl, respectively (91, 92) , and hence the diagnosis of homozygous PS deficiency by fetal blood samplmg should be easier than the diagnosis of severe PC deticiency Such a procedure has not so far been camed out m cases of suspected severe PS deficiency A more direct and precise approach to prenatal diagnosis of severe deficiencies of PC, PS and antithrombm depends pnmanly on the iden tification of the mutaüon or mutations responsible for the disease m the proband and on devismg an easy method for its detection, i e, polymerase cham reaction and restnction analysis or Southern analysis Such work can be performed m highly speciahzed centers that have a partic ular mterest m this issue For Identification of the mutaüon causmg PC deficiency a scannmg method was devised usmg denaturant gradient gel electrophoresis (DGGE) of 13 PCR amphfied fragments that cover exon I and most of the PC codmg regions (93) A sirmlar approach was also used for detection of mutations causmg PS deficiency (94) Once these prerequisites have been met, prenatal diagnosis can be piovided dunng the 9-10th week of gestation by chonomc vülus samplmg and DNA analysis Such an approach was recently used m a family affected by severe PC deficiency (95) and also m a tamily with antithrombm deficiency type IIHBS, m which the fetus was potentially homozygous for a 99 Leu to Phe Substitution and heterozygous for factor V 506Arg to Gin (96) Prenatal exclusion of a severe thrombophiha may also be camed out by mdirect restnction fragment length polymorphism (RFLP) trackmg Such a procedure was used m a family m which a previous mfant died of bilateral renal vem thrombosis and both parents were found to be heterozygotes for PS deficiency (97) linherited Thrombophiha in the Developing Countnes
The prevalence and morbidity of thrombophiha in different geographic regions of the world may be difterent because of genetic racial differences or because the phenotypic expression of the disease is altered by environmental factors While several studies on mhented thrombophiha have been published, these should be mterpreted with caution, due to many problems mvolved m the execution ot the work For example, there are concerns with quahtv control ot laboratory assays, with objective diagnosis of thrombosis and with study design Furthermore, no large epidemiological studies on groups such äs blood donors have been performed m developmg countnes and there are therefore no reasonable estimates of the prevalence of the mhibitor deficiencies Despite these reservations, a number of published reports have attempted to address the issues of frequency of venous thrombosis followmg surgery (98) (99) (100) (101) (102) and of hereditary throbophiha (103) (104) (105) The avaüable data suggests that the prevalence of deep venous thrombosis may be less m the developmg than m the developed countnes However, there are suggestions that patients who do get venous thrombosis are more hkely to have an underlymg mhibitor deficiency Another potentially mterestmg aspect is that early onset of stroke may be associated with mhibitor dehciency (106) Further work is clearly required to consohdate these vanous observations
Conclusions
1 At the present time, mutations in four genes are clearly Imked to increased nsk for venous thromboembolism Many discrete mutations cause deficiencies of antithrombm, PC and PS that dimimsh the capacity to balance procoagulant activity One specific mutation m factor V 506Arg to Gin has a similar impact by rendermg this procoagulant factor resistant to proteolytic degradation With these four estabhshed nsk factors for thrombosis, roughly 50% of the familial thrombophihas can be explamed Apparently a number of other genetic nsk factors so far has escaped detection It is however unhkely that these will be found among deficiencies of plasminogen, heparm cofactor II, tissue factor pathways mhibitor or ß2 glycoprotem I Other candidates will need further evaluation (for mstance, dysfibnnogenemia thrombomodulm defects and mhented hyperhomocystememia) It is mcreasmgly apparent that co-mhentance of more than one relatively mild thrombophilic nsk factor causes more severe clmical expression 2 Increasmgly, attempts are bemg made to assign a magmtude to genetic and acquired nsk factors The nsks estimates that have been found m various studies depend heavily on the way the subjects for those studies were selected and do not necessanly apply to mdividuals selected differently In particular, results from studies among selected famihes with stnking thrombophiha are probably overestimatmg the nsk when apphed to mdividuals who were found because of a smgle thrombotic event The most strmgent selection cntena have been used to ascertam farmlies with the rare abnormahties (PC, PS or antithrombm), which more readily explams the differences found m family studies on these disorders äs compared to APC-R than a true difference m seventy Fmally, when gene-gene and gene-environment mteractions are required to bring about thrombosis, there will be differences withm famihes äs much äs between famihes 3 Laboratory evaluation of thrombophiha should mvolve the use of assays with highest possible sensitivity and specificity for the genetic defect that is to be detected Assays can be of immunological and func tional nature, m the case of immunological assays it should be realized that cases with truly functional defective protems may not be detected A practically useful approach should be taken and the selection of analytical procedures should be govemed by the aim of the mvestiga tion äs well äs of locally determmed tactors such äs prevalence ot the genetic defects to be detected and availabihty ot techmcal suppoit Based on avaüable scientific Information, the laboiatory evaluation should mclude measurements ot PC, total and tree PS, antithrombm and a functional APC R test which is sensitive and specific for the presence of the tactor V 506 Gin allele In the case of PC, assays which are based on its activation with the PC activator Protac and measurements of the active enzyme with synthetic Substrate, fulfil required quality cntena At present no functional PS assays can be recommended for general screenmg of thrombophilic patients Immunological assavs of total äs well äs ot free PS are recommended Recently published results mdicate free PS to be the best marker for genetically determmed PS deficiency but further studies are required before a recommendation only to measure free PS can be made The functional assays for antithrombm which are based on hepann stimulated Inhibition of factor Xa are recommended for screenmg of thrombophilic patients For initial screenmg of APC-R, functional tests are recommended The test can be impro\ed by dilutmg the patient plasma m FV-deficient plasma As assays for PC and PS have distmctly lower sensitivity and specificity for the presence of mhented deficiency durmg the acute thrombotic epidsode and oral anticoagulation, it is at present recommended to perform the laboratory mvesügation for these components after discontmuation of the therapy 4 The clmical mamfestations of the defects of naturally-occumng anticoagulant Systems (antithrombm, PS and PC deficiencies, APC R) are similar In heterozygotes, typical mamfestations are those of venous thromboembolism, such äs deep-vem thrombosis of the legs, pulmonary embohsm and superficial thrombophlebitis Visceral and cerebral vein thrombosis are rarer but quite typical for mhented thrombophiha Patients with homozygous defects have usuallv more severe clmical mam festations with an earlier age of onset Some mamfestations are quite typical for homozygous defects, such äs skm necrosis and widespread neo natal thrombosis m PC and PS deficiencies There are prehminaiy data suggesting that some homozygous defects (antithrombm type IIHBS deficiency) may be also associated with an increased nsk for artenal throm bosis m the young but moie data on this and other homozygous deficiencies are warranted to establish am relationship with artenal disease 5 When a symptomatic patient with mhented thrombophiha due to a known genetic defect is identified family studies should be conducted smce approximately half ot their first-degree relatives will be affected Asymptomatic mdmduals who carry the genetic defect should receive counsellmg regaidmg the imphcations of the diagnosis and Symptoms that reqmre medical attention In general, the manage ment of symptomatic mdividuals with the genetic defect is similar to that for symptomatic patients without an identifiable genetic defect An exception is patients with neonatal purpura fulmmans m association with homozygous or doubly heterozygous PC deficiency m whom the admimstration of a source of PC is cntical m initial treatment Given that future thrombotic events m patients with mhented thrombophiha cannot be accurately predicted and there is a fimte nsk of bleedmg associated with anticoagulant therapy recommendations relatmg to long-term treatment are best mdividuahzed at the current time 6 Once an mdividual is defmed äs bemg affected by hereditary thrombophiha äs many family members äs possible are exammed for the particulai defect detected m the proband and a pedigree is constructed Familv members who are found to be affected are counselled about the nsk of thrombosis An evaluation of the potential nsk of birth of severely atfected newborns is usually carned out m famihes in which mteimarriage is practised, and consequemlv counsellmg, extensive camer detection and prenatal diagnosis is planned and executed
The target tamihes for prenatal diagnosis ot hereditary thrombophillas are those famihes that had already been atflicted by mfants with seveie thrombosis due to homozygositv 01 compound heterozygosity for PC PS or antithrombm detiueni\ äs well äs those famihes mentioned above In these target tamihes an attempt is made to detect the responsible mutation(s), and to de\ise α simple method for their detection, e g, PCR and restnction analysis or Southern analysis This is follovved by an extensive study of family members m the child-bearing age for camership and äs a consequence counselhng is provided Prenatal diagnosis is then based on DNA obtamed by chonomc villus sampling or amniocentesis
In mstances m which the mutation cannot be identified, specific RFLP trackmg m family members and eventually in fetal DNA is an alternative approach In still other mstances of PC or PS deficiency tetal blood sampling at 18-22 weeks of gestation is an Option smce data on the levels ot these components in normal fetuses are available For antithrombm such values are unavailable and thus at present fetal blood sampling for affected famihes cannot be offered, unless the specific mutation has been identified 7 Deep vem thiombosis and pulmonary embohsm have a lower mcidence m the developing world when compared to the West, and this may be due to a combmation of racial and environmental factors There are hmited studies with complete laboratory evaluation on inhented thrombophiha from the developing countnes It appears that there is a higher Chance of finding an underlymg genetic defect (PC PS and anti thiombm deticiency) m patients with thrombosis m the developing world Prelimmary data on APC-R suggests that this defect is rare m Asians, Afncans and Chinese Recommendations 1 Recent reports m the hteratuie support the hypothesis that famihal thrombophiha is a multiple gene disorder and that the penetrance of the disease is higher m camers of multiple gene defects In relation to this it ii> to be expected that prophylactic and therapeutic meas ures need to be adjusted to the number of mdependent nsk factors present in an individual Therefore efforts should be intensified to identify those genetic nsk factors that so far have escaped detection, so that these can be mcluded m diagnostic screenmg procedures 2 Guidelmes need to be developed for the use of specific laboratory tests m screenmg procedures aimmg at the Identification of individuals who carry a genetic nsk factor for venous thrombosis 3 Given the large number of patients that must be followed to detect new abnormalities, collaborative international mvestigations with standardized recruitment protocols should be encouraged 4 More Information Imking genetic causes of hvperhomocystememia to venous thromboembohsm is necessary 5 An estimate of the prevalence of PS deficiency m the population would help evaluate its relative nsk 6 More specific recommendations need to be developed for the classification of hereditary PS deficiencv Within this context it needs to be established whether so called type III PS deficiency is an mdependent nsk factor for venous thrombosis or a different phenotype of type I PS deficiency 7 As recent data suggest that measuiement ot free PS may be more valuable than total PS assays toi the diagnosis of PS deficiency, it is recommended that studies are pertormed which evaluate the performance of different methods tor determmation of free PS 8 General screenmg of the population tor genetic defects of PC, PS and antithrombm can at present not be lecommended mainly based on the low prevalence of these detects m the population and on the low predictive value of a positive test It is recommended that studies are performed which address the question whether general screenmg for APC R (FV 506 Gin allele) e g betoie oral contraception, surgery or hospitahzation is beneticial toi the decision on therapeutic and prophylaUic legimes 
